{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:57:22Z","timestamp":1783702642995,"version":"3.55.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830006"],"award-info":[{"award-number":["81830006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Translational Research Grant of HCRCH","award":["2020ZKZC01"],"award-info":[{"award-number":["2020ZKZC01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T-cell lymphomas (PTCLs) are biologically and clinically heterogeneous diseases almost all of which are associated with poor outcomes. Recent advances in gene expression profiling that helps in diagnosis and prognostication of different subtypes and next-generation sequencing have given new insights into the pathogenesis and molecular pathway of PTCL. Here, we focus on a broader description of mutational insights into the common subtypes of PTCL including PTCL not other specified type, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, and extra-nodal NK\/T cell lymphoma, nasal type, and also present an overview of new targeted therapies currently in various stages of clinical trials.<\/jats:p>","DOI":"10.1186\/s40164-020-00188-w","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:03:23Z","timestamp":1605265403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Caiqin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-6674","authenticated-orcid":false,"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"issue":"20","key":"188_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"15","key":"188_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376.","journal-title":"Blood"},{"issue":"9","key":"188_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","volume":"23","author":"K Laribi","year":"2018","unstructured":"Laribi K, Alani M, Truong C, Baugier de Materre A. Recent advances in the treatment of peripheral T-Cell lymphoma. Oncologist. 2018;23(9):1039\u201353.","journal-title":"Oncologist"},{"issue":"25","key":"188_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"188_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.16428","volume":"189","author":"MA Timmins","year":"2020","unstructured":"Timmins MA, Wagner SD, Ahearne MJ. The new biology of PTCL-NOS and AITL: current status and future clinical impact. Br J Haematol. 2020;189(1):54\u201366.","journal-title":"Br J Haematol"},{"issue":"5","key":"188_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, International Peripheral T-Cell Lymphoma Project, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026\u201336.","journal-title":"Blood"},{"issue":"19","key":"188_CR7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915\u201323.","journal-title":"Blood"},{"issue":"1","key":"188_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","volume":"13","author":"E Mulvey","year":"2020","unstructured":"Mulvey E, Ruan J. Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol. 2020;13(1):59.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"188_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronne","year":"2012","unstructured":"Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"188_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135.","journal-title":"Nat Genet"},{"issue":"7","key":"188_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, Ja\u00efs JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466\u20139.","journal-title":"Blood"},{"issue":"22","key":"188_CR12","doi-asserted-by":"publisher","first-page":"16124","DOI":"10.18632\/oncotarget.24592","volume":"9","author":"R Manso","year":"2018","unstructured":"Manso R, Gonzalez-Rincon J, Rodriguez-Justo M, Roncador G, Gomez S, Sanchez-Beato M, et al. Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features. Oncotarget. 2018;9(22):16124\u201333.","journal-title":"Oncotarget"},{"key":"188_CR13","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33:2867\u201383.","journal-title":"Leukemia"},{"issue":"12","key":"188_CR14","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/bcj.2014.83","volume":"4","author":"H Muto","year":"2014","unstructured":"Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4(12):e264.","journal-title":"Blood Cancer J"},{"issue":"1","key":"188_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/leu.2014.261","volume":"29","author":"JH Schatz","year":"2015","unstructured":"Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, et al. Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2015;29(1):237\u201341.","journal-title":"Leukemia"},{"issue":"6","key":"188_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/PAI.0000000000000644","volume":"27","author":"S Fernandez-Pol","year":"2019","unstructured":"Fernandez-Pol S, Ma L, Joshi RP, Arber DA. a survey of somatic mutations in 41 genes in a cohort of T-cell lymphomas identifies frequent mutations in genes involved in epigenetic modification. Appl Immunohistochem Mol Morphol. 2019;27(6):416\u201322.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"188_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3324\/haematol.2017.182444","volume":"103","author":"MM Ji","year":"2018","unstructured":"Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679\u201387.","journal-title":"Haematologica"},{"issue":"1","key":"188_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","volume":"7","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7(1):38\u201353.","journal-title":"Cancer Discov"},{"issue":"2","key":"188_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370.","journal-title":"Nat Genet"},{"issue":"4","key":"188_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371\u20135.","journal-title":"Nat Genet"},{"issue":"18","key":"188_CR21","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1182\/blood-2014-02-555946","volume":"123","author":"R Manso","year":"2014","unstructured":"Manso R, S\u00e1nchez-Beato M, Monsalvo S, G\u00f3mez S, Cereceda L, Llamas P, et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood. 2014;123(18):2893\u20134.","journal-title":"Blood"},{"issue":"2","key":"188_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41379-019-0279-8","volume":"33","author":"MA Laginestra","year":"2020","unstructured":"Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, et al. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Mod Pathol. 2020;33(2):179\u201387.","journal-title":"Mod Pathol"},{"issue":"4","key":"188_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","volume":"19","author":"RF Sandell","year":"2017","unstructured":"Sandell RF, Boddicker RL, Feldman AL. Genetic Landscape and Classification of Peripheral T Cell Lymphomas. Curr Oncol Rep. 2017;19(4):28.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"188_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1073\/pnas.1608839114","volume":"114","author":"F Abate","year":"2017","unstructured":"Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proc Natl Acad Sci USA. 2017;114(4):764\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"188_CR25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, Komori D, Gershon P, Kiryu M, et al. Activation of RHOA\u2013VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018;32(3):694\u2013702.","journal-title":"Leukemia"},{"issue":"48","key":"188_CR26","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004;23(48):7990\u20138000.","journal-title":"Oncogene"},{"issue":"5","key":"188_CR27","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.4049\/jimmunol.171.5.2225","volume":"171","author":"LI Salazar-Fontana","year":"2003","unstructured":"Salazar-Fontana LI, Barr V, Samelson LE, Bierer BE. CD28 engagement promotes actin polymerization through the activation of the small Rho GTPase Cdc42 in human T cells. J Immunol. 2003;171(5):2225\u201332.","journal-title":"J Immunol"},{"issue":"6","key":"188_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3324\/haematol.2015.139253","volume":"101","author":"HY Yoo","year":"2016","unstructured":"Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, et al. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica. 2016;101(6):757\u201363.","journal-title":"Haematologica"},{"issue":"11","key":"188_CR29","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, Reynies AD, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952\u201363.","journal-title":"Blood"},{"key":"188_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-99716-2_2","volume":"176","author":"J Iqbal","year":"2019","unstructured":"Iqbal J, Amador C, McKeithan TW, Chan WC. Molecular and genomic landscape of peripheral T-cell lymphoma. Cancer Treat Res. 2019;176:31\u201368.","journal-title":"Cancer Treat Res"},{"issue":"8","key":"188_CR31","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ajh.25513","volume":"94","author":"JM Zain","year":"2019","unstructured":"Zain JM. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(8):929\u201346.","journal-title":"Am J Hematol"},{"issue":"8","key":"188_CR32","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, Kucuk C, De Leval L, Jais J-P, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901\u20133.","journal-title":"Blood"},{"issue":"9","key":"188_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136.","journal-title":"Blood"},{"issue":"15","key":"188_CR34","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741\u201352.","journal-title":"Blood"},{"issue":"26","key":"188_CR35","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477\u201387.","journal-title":"N Engl J Med"},{"issue":"52","key":"188_CR36","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1073\/pnas.1617929114","volume":"113","author":"F Lemonnier","year":"2016","unstructured":"Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, Broutin S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci USA. 2016;113(52):15084\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"188_CR37","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","volume":"102","author":"MP Dobay","year":"2017","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102(4):e148\u201351.","journal-title":"Haematologica"},{"issue":"10","key":"188_CR38","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","volume":"34","author":"S Chiba","year":"2020","unstructured":"Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34(10):2592\u2013606.","journal-title":"Leukemia"},{"issue":"11","key":"188_CR39","doi-asserted-by":"publisher","first-page":"17763","DOI":"10.18632\/oncotarget.14846","volume":"8","author":"M Wang","year":"2017","unstructured":"Wang M, Zhang S, Chuang SS, Ashton-Key M, Ochoa E, Bolli N, et al. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. Oncotarget. 2017;8(11):17763\u201370.","journal-title":"Oncotarget"},{"issue":"3","key":"188_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/path.5376","volume":"250","author":"WQ Yao","year":"2020","unstructured":"Yao WQ, Wu F, Zhang W, Chuang SS, Thompson JS, Chen Z, et al. Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2020;250(3):346\u201357.","journal-title":"J Pathol"},{"key":"188_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-017-0085-8","volume":"5","author":"M Willemsen","year":"2017","unstructured":"Willemsen M, Schouten HC. Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. Biomark Res. 2017;5:6.","journal-title":"Biomark Res"},{"issue":"2","key":"188_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, Quinn SA, Kim CS, da Silva Almeida AC, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(2):259-73.e7.","journal-title":"Cancer Cell"},{"issue":"1","key":"188_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-017-0047-2","volume":"8","author":"M Willemsen","year":"2018","unstructured":"Willemsen M, Abdul Hamid M, Winkens B, Zur HA. Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. Blood Cancer J. 2018;8(1):6.","journal-title":"Blood Cancer J"},{"issue":"9","key":"188_CR44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng SY, Brown L, Stevenson K, deSouza T, Aster JC, Louissaint A Jr, Weinstock DM. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood. 2018;132(9):935\u201347.","journal-title":"Blood"},{"issue":"3","key":"188_CR45","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/cas.13393","volume":"109","author":"K Fukumoto","year":"2018","unstructured":"Fukumoto K, Nguyen TB, Chiba S, Sakata-Yanagimoto M. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. Cancer Sci. 2018;109(3):490\u20136.","journal-title":"Cancer Sci"},{"issue":"101","key":"188_CR46","doi-asserted-by":"publisher","first-page":"ra83","DOI":"10.1126\/scisignal.2000420","volume":"2","author":"A Saveliev","year":"2009","unstructured":"Saveliev A, Vanes L, Ksionda O, Rapley J, Smerdon SJ, Rittinger K, et al. Function of the nucleotide exchange activity of vav1 in T cell development and activation. Sci Signal. 2009;2(101):ra83.","journal-title":"Sci Signal"},{"issue":"20","key":"188_CR47","doi-asserted-by":"publisher","first-page":"10923","DOI":"10.1073\/pnas.97.20.10923","volume":"97","author":"J Huang","year":"2000","unstructured":"Huang J, Tilly D, Altman A, Sugie K, Grey HM. T-cell receptor antagonists induce Vav phosphorylation by selective activation of Fyn kinase. Proc Natl Acad Sci USA. 2000;97(20):10923\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"188_CR48","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2015.357","volume":"30","author":"J Rohr","year":"2016","unstructured":"Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia. 2016;30(5):1062\u201370.","journal-title":"Leukemia"},{"issue":"4","key":"188_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/cancers10040107","volume":"10","author":"IA Montes-Mojarro","year":"2018","unstructured":"Montes-Mojarro IA, Steinhilber J, Bonzheim I, Quintanilla-Martinez L, Fend F. The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL). Cancers (Basel). 2018;10(4):107.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"188_CR50","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12185-013-1407-8","volume":"98","author":"SM Chan","year":"2013","unstructured":"Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1\/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol. 2013;98(6):648\u201357.","journal-title":"Int J Hematol"},{"issue":"8","key":"188_CR51","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732\u20136.","journal-title":"Am J Hematol"},{"issue":"2","key":"188_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","volume":"83","author":"AJ Ferreri","year":"2012","unstructured":"Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012;83(2):293\u2013302.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"188_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","volume":"126","author":"G Hapgood","year":"2015","unstructured":"Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17\u201325.","journal-title":"Blood"},{"key":"188_CR54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fonc.2020.00898","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Lee D, Brimer T, Hussaini M, Sokol L. Genomics of peripheral T-cell lymphoma and its implications for personalized medicine. Front Oncol. 2020;10:898.","journal-title":"Front Oncol"},{"issue":"6","key":"188_CR55","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/leu.2014.347","volume":"29","author":"F Abate","year":"2015","unstructured":"Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, European T-cell Lymphoma Study Group, et al. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia. 2015;29(6):1390\u2013401.","journal-title":"Leukemia"},{"issue":"9","key":"188_CR56","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124(9):1473\u201380.","journal-title":"Blood"},{"issue":"7","key":"188_CR57","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1158\/1535-7163.MCT-11-0042","volume":"10","author":"O Merkel","year":"2011","unstructured":"Merkel O, Hamacher F, Sifft E, Kenner L, Greil R, European Research Initiative on Anaplastic Large Cell Lymphoma. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther. 2011;10(7):1127\u201336.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"188_CR58","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo R, Abate F, Lasorsa E, Tabbo\u2019 F, Gaudiano M, Chiesa N, European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium \u201cGenetics-Driven Targeted Management of Lymphoid Malignancies,\u201d et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516\u201332.","journal-title":"Cancer Cell"},{"issue":"11","key":"188_CR59","doi-asserted-by":"publisher","first-page":"18525","DOI":"10.18632\/oncotarget.14503","volume":"8","author":"E Mereu","year":"2017","unstructured":"Mereu E, Pellegrino E, Scarf\u00f2 I, Inghirami G, Piva R. The heterogeneous landscape of ALK negative ALCL. Oncotarget. 2017;8(11):18525\u201336.","journal-title":"Oncotarget"},{"issue":"2","key":"188_CR60","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2014-12-614503","volume":"127","author":"I Scarf\u00f2","year":"2016","unstructured":"Scarf\u00f2 I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, European T-Cell Lymphoma Study Group, et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood. 2016;127(2):221\u201332.","journal-title":"Blood"},{"issue":"3","key":"188_CR61","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/cancers12030702","volume":"12","author":"EI Andersson","year":"2020","unstructured":"Andersson EI, Br\u00fcck O, Braun T, Mannisto S, Saikko L, Lagstr\u00f6m S, et al. STAT3 mutation is associated with STAT3 activation in CD30+ ALK- ALCL. Cancers (Basel). 2020;12(3):702.","journal-title":"Cancers (Basel)"},{"key":"188_CR62","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238766","author":"H Larose","year":"2020","unstructured":"Larose H, Prokoph N, Matthews JD, Schlederer M, H\u00f6gler S, Alsulami AF, et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2020. https:\/\/doi.org\/10.3324\/haematol.2019.238766.","journal-title":"Haematologica"},{"issue":"11","key":"188_CR63","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1002\/cam4.3037","volume":"9","author":"W Liu","year":"2020","unstructured":"Liu W, Ji X, Song Y, Wang X, Zheng W, Lin N, et al. Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades. Cancer Med. 2020;9(11):3765\u201374.","journal-title":"Cancer Med"},{"issue":"6","key":"188_CR64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11899-016-0355-9","volume":"11","author":"BM Haverkos","year":"2016","unstructured":"Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M, et al. Extranodal NK\/T-cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep. 2016;11(6):514\u201327.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"188_CR65","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/ijms19071931","volume":"19","author":"S de Mel","year":"2018","unstructured":"de Mel S, Soon GS, Mok Y, Chung TH, Jeyasekharan AD, Chng WJ, et al. The genomics and molecular biology of natural killer\/T-cell lymphoma: opportunities for translation. Int J Mol Sci. 2018;19(7):1931.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"188_CR66","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(16)30148-6","volume":"17","author":"Z Li","year":"2016","unstructured":"Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240\u20137.","journal-title":"Lancet Oncol"},{"issue":"1","key":"188_CR67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-019-0716-7","volume":"12","author":"S de Mel","year":"2019","unstructured":"de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB. Molecular pathogenic pathways in extranodal NK\/T cell lymphoma. J Hematol Oncol. 2019;12(1):33.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"188_CR68","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","volume":"118","author":"K Karube","year":"2011","unstructured":"Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K, Nakashima Y, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118(12):3195\u2013204.","journal-title":"Blood"},{"issue":"6","key":"188_CR69","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/leu.2009.3","volume":"23","author":"J Iqbal","year":"2009","unstructured":"Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W, Geng H, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23(6):1139\u201351.","journal-title":"Leukemia"},{"issue":"6","key":"188_CR70","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","volume":"115","author":"Y Huang","year":"2010","unstructured":"Huang Y, de Reyni\u00e8s A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type. Blood. 2010;115(6):1226\u201337.","journal-title":"Blood"},{"issue":"4","key":"188_CR71","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.2823","volume":"223","author":"SB Ng","year":"2011","unstructured":"Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK\/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011;223(4):496\u2013510.","journal-title":"J Pathol"},{"issue":"9","key":"188_CR72","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47(9):1061\u20136.","journal-title":"Nat Genet"},{"issue":"3","key":"188_CR73","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5808\/GI.2016.14.3.78","volume":"14","author":"S Choi","year":"2016","unstructured":"Choi S, Go JH, Kim EK, Lee H, Lee WM, Cho CS, Han K. Mutational analysis of extranodal NK\/T-cell lymphoma using targeted sequencing with a comprehensive cancer panel. Genomics Inform. 2016;14(3):78\u201384.","journal-title":"Genomics Inform"},{"issue":"10","key":"188_CR74","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/15384047.2019.1638670","volume":"20","author":"LM Gao","year":"2019","unstructured":"Gao LM, Zhao S, Zhang WY, Wang M, Li HF, Lizaso A, et al. Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders. Cancer Biol Ther. 2019;20(10):1319\u201327.","journal-title":"Cancer Biol Ther"},{"issue":"19","key":"188_CR75","doi-asserted-by":"publisher","first-page":"17764","DOI":"10.18632\/oncotarget.3776","volume":"6","author":"S Lee","year":"2015","unstructured":"Lee S, Park HY, Kang SY, Kim SJ, Hwang J, Lee S, et al. Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764\u201376.","journal-title":"Oncotarget"},{"issue":"5","key":"188_CR76","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajpath.2017.01.004","volume":"187","author":"SH Sim","year":"2017","unstructured":"Sim SH, Kim S, Kim TM, Jeon YK, Nam SJ, Ahn YO, et al. Novel JAK3-activating mutations in extranodal NK\/T-cell lymphoma, Nasal Type. Am J Pathol. 2017;187(5):980\u20136.","journal-title":"Am J Pathol"},{"issue":"7","key":"188_CR77","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","volume":"2","author":"GC Koo","year":"2012","unstructured":"Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, et al. Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma. Cancer Discov. 2012;2(7):591\u20137.","journal-title":"Cancer Discov"},{"key":"188_CR78","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/ncomms7025","volume":"6","author":"C K\u00fc\u00e7\u00fck","year":"2015","unstructured":"K\u00fc\u00e7\u00fck C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells. Nat Commun. 2015;6:6025.","journal-title":"Nat Commun"},{"issue":"11","key":"188_CR79","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL, Nairism\u00e4gi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood. 2018;132(11):1146\u201358.","journal-title":"Blood"},{"issue":"3","key":"188_CR80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020;37(3):403-19.e6.","journal-title":"Cancer Cell"},{"issue":"10","key":"188_CR81","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","volume":"125","author":"YW Chen","year":"2015","unstructured":"Chen YW, Guo T, Shen L, Wong KY, Tao Q, Choi WW, et al. Receptor-type tyrosine-protein phosphatase \u03ba directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma. Blood. 2015;125(10):1589\u2013600.","journal-title":"Blood"},{"issue":"1","key":"188_CR82","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol Oncol. 2016;9(1):109.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"188_CR83","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","volume":"131","author":"JS Van Arnam","year":"2018","unstructured":"Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ. Novel insights into the pathogenesis of T-cell lymphomas. Blood. 2018;131(21):2320\u201330.","journal-title":"Blood"},{"issue":"9","key":"188_CR84","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3109\/10428194.2013.876629","volume":"55","author":"L Han","year":"2014","unstructured":"Han L, Li L, Wu J, Li X, Zhang L, Wang X, et al. Clinical features and treatment of natural killer\/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. Leuk Lymphoma. 2014;55(9):2048\u201355.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"188_CR85","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.12823","volume":"165","author":"H Sano","year":"2014","unstructured":"Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, et al. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study. Br J Haematol. 2014;165(6):786\u201392.","journal-title":"Br J Haematol"},{"issue":"2","key":"188_CR86","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nm.4456","volume":"24","author":"H Wen","year":"2018","unstructured":"Wen H, Ma H, Cai Q, Lin S, Lei X, He B, et al. Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK\/T cell lymphoma. Nat Med. 2018;24(2):154\u201364.","journal-title":"Nat Med"},{"issue":"7","key":"188_CR87","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92(7):706\u201315.","journal-title":"Am J Hematol"},{"issue":"10","key":"188_CR88","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005;103(10):2091\u20138.","journal-title":"Cancer"},{"issue":"2","key":"188_CR89","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.hoc.2016.11.009","volume":"31","author":"M Al-Zahrani","year":"2017","unstructured":"Al-Zahrani M, Savage KJ. Peripheral T-cell lymphoma, not otherwise specified: a review of current disease understanding and therapeutic approaches. Hematol Oncol Clin N Am. 2017;31(2):189\u2013207.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"2","key":"188_CR90","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4143\/crt.2019.198","volume":"52","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom HS, et al. Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-hodgkin lymphomas: results of a multicenter, open-labeled phase II trial. Cancer Res Treat. 2020;52(2):374\u201387.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"188_CR91","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/ejh.13368","volume":"104","author":"SM Wagner","year":"2020","unstructured":"Wagner SM, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P, et al. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. Eur J Haematol. 2020;104(3):251\u20138.","journal-title":"Eur J Haematol"},{"issue":"8","key":"188_CR92","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1080\/10428194.2018.1562184","volume":"60","author":"J Roswarski","year":"2019","unstructured":"Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, et al. Phase 1\/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Leuk Lymphoma. 2019;60(8):2062\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"188_CR93","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/10428190903580402","volume":"51","author":"E Weidmann","year":"2010","unstructured":"Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, et al. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma. 2010;51(3):447\u201355.","journal-title":"Leuk Lymphoma"},{"key":"188_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0838-5","author":"GG Wulf","year":"2020","unstructured":"Wulf GG, Altmann B, Ziepert M, D\u2019Amore F, Held G, Greil R, ACT-2 study investigators, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006\u20131B\/ACT-2 trial. Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-020-0838-5.","journal-title":"Leukemia"},{"key":"188_CR95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fonc.2018.00139","volume":"8","author":"B Hu","year":"2018","unstructured":"Hu B, Oki Y. Novel immunotherapy options for extranodal NK\/T-cell lymphoma. Front Oncol. 2018;8:139.","journal-title":"Front Oncol"},{"issue":"11","key":"188_CR96","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.14.94","volume":"6","author":"M Remer","year":"2014","unstructured":"Remer M, Al-Shamkhani A, Glennie M, Johnson P. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immunotherapy. 2014;6(11):1187\u2013206.","journal-title":"Immunotherapy"},{"issue":"11","key":"188_CR97","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363.","journal-title":"J Clin Oncol"},{"issue":"52","key":"188_CR98","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","volume":"105","author":"M Marzec","year":"2008","unstructured":"Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7\u2013H1). Proc Natl Acad Sci USA. 2008;105(52):20852\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"188_CR99","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","volume":"19","author":"SK Barta","year":"2019","unstructured":"Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(6):356-64.e3.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"188_CR100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"188_CR101","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","volume":"12","author":"LC Fleischer","year":"2019","unstructured":"Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12(1):141.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"188_CR102","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","volume":"19","author":"NS Grover","year":"2019","unstructured":"Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19(1):203.","journal-title":"BMC Cancer"},{"issue":"9","key":"188_CR103","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462\u201371.","journal-title":"J Clin Invest"},{"issue":"3","key":"188_CR104","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"16","key":"188_CR105","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"188_CR106","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416\u201323.","journal-title":"Nat Med"},{"issue":"23","key":"188_CR107","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"188_CR108","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3322\/caac.21589","volume":"70","author":"E Marchi","year":"2020","unstructured":"Marchi E, O\u2019Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin. 2020;70(1):47\u201370.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"188_CR109","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371.","journal-title":"Ann Oncol"},{"issue":"19","key":"188_CR110","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4(19):4640\u20137.","journal-title":"Blood Adv"},{"issue":"21","key":"188_CR111","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305\u20139.","journal-title":"Blood"},{"issue":"2","key":"188_CR112","doi-asserted-by":"publisher","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","volume":"106","author":"C Gambacorti Passerini","year":"2014","unstructured":"Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt378.","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"188_CR113","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Moss\u00e9","year":"2017","unstructured":"Moss\u00e9 YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\u2019s oncology group study. J Clin Oncol. 2017;35(28):3215\u201321.","journal-title":"J Clin Oncol"},{"issue":"8","key":"188_CR114","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888\u201398.","journal-title":"Blood"},{"issue":"9","key":"188_CR115","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","volume":"80","author":"TB Nguyen","year":"2020","unstructured":"Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, Nuhat ST, Miyoshi H, Nannya Y, et al. Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma. Cancer Res. 2020;80(9):1875\u201384.","journal-title":"Cancer Res"},{"issue":"17","key":"188_CR116","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O'Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395\u2013405.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-020-00188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40164-020-00188-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-020-00188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:09:40Z","timestamp":1605265780000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-020-00188-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1186\/s40164-020-00188-w","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}